Success Metrics

Clinical Success Rate

100.0%

Based on 9 completed trials

Completion Rate

100%(9/9)

Active Trials

0(0%)

Results Posted

33%(3 trials)

Phase Distribution

Ph phase_2

67%

Ph phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

3(33.3%)

Phase 2Efficacy & side effects

6(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (33.3%)

Phase 26 (66.7%)

Trials by Status

completed9100%

Recent Activity

0 active trials

Showing 5 of 9

completedphase_1

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

NCT00243087

completedphase_1

Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit

NCT02211859

completedphase_2

BI 2536 Second Line Monotherapy in SCLC

NCT00412880

completedphase_2

Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer

NCT00376623

completedphase_2

Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

NCT00710710

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT00243087Phase 1

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Completed

NCT02211859Phase 1

Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit

Completed

NCT00412880Phase 2

BI 2536 Second Line Monotherapy in SCLC

Completed

NCT00376623Phase 2

Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer

Completed

NCT00710710Phase 2

Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

Completed

NCT02211833Phase 1

Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer

Completed

NCT00706498Phase 2

Phase II Study of BI 2536 in Prostate Cancer

Completed

NCT00701766Phase 2

BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia

Completed

NCT00526149Phase 2

BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors